<?xml version="1.0" encoding="utf-8"?>
<doi_batch version="4.4.2" xmlns="http://www.crossref.org/schema/4.4.2" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.crossref.org/schema/4.4.2 http://data.crossref.org/schemas/crossref4.4.2.xsd" xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1">
  <head>
    <doi_batch_id>0000000000000000000000000000000000000000000000000000000000000000</doi_batch_id>
    <timestamp>1605068020541</timestamp>
    <depositor>
      <depositor_name>Stencila</depositor_name>
      <email_address>doi@stenci.la</email_address>
    </depositor>
    <registrant>Stencila</registrant>
  </head>
  <body>
    <posted_content type="preprint">
      <group_title>Article</group_title>
      <contributors>
        <person_name contributor_role="author" sequence="first">
          <given_name>Lucía</given_name>
          <surname>Trilla-Fuertes</surname>
        </person_name>
        <person_name contributor_role="author" sequence="additional">
          <given_name>Natalia</given_name>
          <surname>Miranda</surname>
        </person_name>
        <person_name contributor_role="author" sequence="additional">
          <given_name>Daniel</given_name>
          <surname>Castellano</surname>
        </person_name>
        <person_name contributor_role="author" sequence="additional">
          <given_name>Rocío</given_name>
          <surname>López-Vacas</surname>
        </person_name>
        <person_name contributor_role="author" sequence="additional">
          <given_name>Carlos A.</given_name>
          <surname>Farfán Tello</surname>
        </person_name>
        <person_name contributor_role="author" sequence="additional">
          <given_name>Guillermo</given_name>
          <surname>de Velasco</surname>
        </person_name>
        <person_name contributor_role="author" sequence="additional">
          <given_name>Felipe</given_name>
          <surname>Villacampa</surname>
        </person_name>
        <person_name contributor_role="author" sequence="additional">
          <given_name>Elena</given_name>
          <surname>López-Camacho</surname>
        </person_name>
        <person_name contributor_role="author" sequence="additional">
          <given_name>Guillermo</given_name>
          <surname>Prado-Vázquez</surname>
        </person_name>
        <person_name contributor_role="author" sequence="additional">
          <given_name>Andrea</given_name>
          <surname>Zapater-Moros</surname>
        </person_name>
        <person_name contributor_role="author" sequence="additional">
          <given_name>Enrique</given_name>
          <surname>Espinosa</surname>
        </person_name>
        <person_name contributor_role="author" sequence="additional">
          <given_name>Juan Ángel</given_name>
          <surname>Fresno Vara</surname>
        </person_name>
        <person_name contributor_role="author" sequence="additional">
          <given_name>Álvaro</given_name>
          <surname>Pinto</surname>
        </person_name>
        <person_name contributor_role="author" sequence="additional">
          <given_name>Angelo</given_name>
          <surname>Gámez-Pozo</surname>
        </person_name>
      </contributors>
      <titles>
        <title>miRNA profiling in renal carcinoma suggest the existence of a group of pro-angionenic tumors in localized clear cell renal carcinoma</title>
      </titles>
      <posted_date>
        <month>02</month>
        <day>28</day>
        <year>2020</year>
      </posted_date>
      <acceptance_date>
        <month>01</month>
        <day>28</day>
        <year>2020</year>
      </acceptance_date>
      <abstract xmlns="http://www.ncbi.nlm.nih.gov/JATS1">
        <p>Renal cell carcinoma comprises a variety of entities, the most common being the clear-cell, papillary and chromophobe subtypes. These subtypes are related to different clinical evolution; however, most therapies have been developed for clear-cell carcinoma and there is not a specific treatment based on different subtypes. In this study, one hundred and sixty-four paraffin samples from primary nephrectomies for localized tumors were analyzed. MiRNAs were isolated and measured by microRNA arrays. Significance Analysis of Microarrays and Consensus Cluster algorithm were used to characterize different renal subtypes. The analyses showed that chromophobe renal tumors are a homogeneous group characterized by an overexpression of miR 1229, miR 10a, miR 182, miR 1208, miR 222, miR 221, miR 891b, miR 629-5p and miR 221-5p. On the other hand, clear cell renal carcinomas presented two different groups inside this histological subtype, with differences in miRNAs that regulate focal adhesion, transcription, apoptosis and angiogenesis processes. Specifically, one of the defined groups had an overexpression of proangiogenic microRNAs miR185, miR126 and miR130a. In conclusion, differences in miRNA expression profiles between histological renal subtypes were established. In addition, clear cell renal carcinomas had different expression of proangiogenic miRNAs. With the emergence of antiangiogenic drugs, these differences could be used as therapeutic targets in the future or as a selection method for tailoring personalized treatments.</p>
      </abstract>
      <doi_data>
        <doi>10.5555/12345</doi>
        <resource>https://example.org</resource>
      </doi_data>
      <citation_list>
        <citation key="ref1">
          <journal_title>CA Cancer J Clin</journal_title>
          <author>Siegel</author>
          <volume>69</volume>
          <issue>1</issue>
          <cYear>2019</cYear>
          <article_title>Cancer statistics, 2019</article_title>
        </citation>
        <citation key="ref2">
          <journal_title>Urol Clin North Am</journal_title>
          <author>Janzen</author>
          <volume>30</volume>
          <issue>4</issue>
          <cYear>2003</cYear>
          <article_title>Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease</article_title>
        </citation>
        <citation key="ref3">
          <journal_title>Semin Oncol</journal_title>
          <author>Janowitz</author>
          <volume>40</volume>
          <issue>4</issue>
          <cYear>2013</cYear>
          <article_title>Adjuvant therapy in renal cell carcinoma-past, present, and future</article_title>
        </citation>
        <citation key="ref4">
          <journal_title>Ann Oncol</journal_title>
          <author>Staehler</author>
          <volume>29</volume>
          <issue>10</issue>
          <cYear>2018</cYear>
          <article_title>Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial</article_title>
        </citation>
        <citation key="ref5">
          <journal_title>Kidney Cancer</journal_title>
          <author>Lawrence</author>
          <volume>2</volume>
          <issue>2</issue>
          <cYear>2018</cYear>
          <article_title>What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial</article_title>
        </citation>
        <citation key="ref6">
          <journal_title>J Clin Oncol</journal_title>
          <author>Motzer</author>
          <volume>35</volume>
          <issue>35</issue>
          <cYear>2017</cYear>
          <article_title>Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma</article_title>
        </citation>
        <citation key="ref7">
          <journal_title>Ann Oncol</journal_title>
          <author>Gross-Goupil</author>
          <volume>29</volume>
          <issue>12</issue>
          <cYear>2018</cYear>
          <article_title>Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial</article_title>
        </citation>
        <citation key="ref8">
          <journal_title>Eur Urol</journal_title>
          <author>Moch</author>
          <volume>70</volume>
          <issue>1</issue>
          <cYear>2016</cYear>
          <article_title>The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours</article_title>
        </citation>
        <citation key="ref9">
          <journal_title>Cell Rep</journal_title>
          <author>Ricketts</author>
          <volume>23</volume>
          <issue>1</issue>
          <cYear>2018</cYear>
          <article_title>The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma</article_title>
        </citation>
        <citation key="ref10">
          <journal_title>N Engl J Med</journal_title>
          <author>Linehan</author>
          <volume>374</volume>
          <issue>2</issue>
          <cYear>2016</cYear>
          <article_title>Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma</article_title>
        </citation>
        <citation key="ref11">
          <journal_title>J Hematol Oncol</journal_title>
          <author>Wang</author>
          <volume>7</volume>
          <cYear>2014</cYear>
          <article_title>Circulating miRNAs in cancer: from detection to therapy</article_title>
        </citation>
        <citation key="ref12">
          <journal_title>PLoS One</journal_title>
          <author>Kakimoto</author>
          <volume>11</volume>
          <issue>9</issue>
          <cYear>2016</cYear>
          <article_title>MicroRNA Stability in FFPE Tissue Samples: Dependence on GC Content</article_title>
        </citation>
        <citation key="ref13">
          <journal_title>Clin Epigenetics</journal_title>
          <author>Si</author>
          <volume>11</volume>
          <issue>1</issue>
          <cYear>2019</cYear>
          <article_title>The role and mechanisms of action of microRNAs in cancer drug resistance</article_title>
        </citation>
        <citation key="ref14">
          <journal_title>Annu Rev Pathol</journal_title>
          <author>Lee</author>
          <volume>4</volume>
          <cYear>2009</cYear>
          <article_title>MicroRNAs in cancer</article_title>
        </citation>
        <citation key="ref15">
          <journal_title>Cancer Res</journal_title>
          <author>Gámez-Pozo</author>
          <cYear>2015</cYear>
          <article_title>Combined label-free quantitative proteomics and microRNA expression analysis of breast cancer unravel molecular differences with clinical implications</article_title>
        </citation>
        <citation key="ref16">
          <journal_title>Neoplasia</journal_title>
          <author>Gámez-Pozo</author>
          <volume>14</volume>
          <issue>12</issue>
          <cYear>2012</cYear>
          <article_title>MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients</article_title>
        </citation>
        <citation key="ref17">
          <journal_title>BMC Res Notes</journal_title>
          <author>López-Romero</author>
          <volume>3</volume>
          <cYear>2010</cYear>
          <article_title>Processing of Agilent microRNA array data</article_title>
        </citation>
        <citation key="ref18">
          <journal_title>Biostatistics</journal_title>
          <author>Johnson</author>
          <volume>8</volume>
          <issue>1</issue>
          <cYear>2007</cYear>
          <article_title>Adjusting batch effects in microarray expression data using empirical Bayes methods</article_title>
        </citation>
        <citation key="ref19">
          <journal_title>Machine learning</journal_title>
          <author>Monti</author>
          <volume>52</volume>
          <issue>1</issue>
          <cYear>2003</cYear>
          <article_title>Consensus Clustering: A Resampling-Based Method for Class Discovery and Visualization of Gene Expression Microarray Data</article_title>
        </citation>
        <citation key="ref20">
          <journal_title>Biotechniques</journal_title>
          <author>Saeed</author>
          <volume>34</volume>
          <issue>2</issue>
          <cYear>2003</cYear>
          <article_title>TM4: a free, open-source system for microarray data management and analysis</article_title>
        </citation>
        <citation key="ref21">
          <journal_title>Proc Natl Acad Sci U S A</journal_title>
          <author>Tusher</author>
          <volume>98</volume>
          <issue>9</issue>
          <cYear>2001</cYear>
          <article_title>Significance analysis of microarrays applied to the ionizing radiation response</article_title>
        </citation>
        <citation key="ref22">
          <journal_title>J Biomed Inform</journal_title>
          <author>Dweep</author>
          <volume>44</volume>
          <issue>5</issue>
          <cYear>2011</cYear>
          <article_title>miRWalk—database: prediction of possible miRNA binding sites by "walking" the genes of three genomes</article_title>
        </citation>
        <citation key="ref23">
          <journal_title>BMC Bioinformatics</journal_title>
          <author>Chen</author>
          <volume>14</volume>
          <cYear>2013</cYear>
          <article_title>Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool</article_title>
        </citation>
        <citation key="ref24">
          <journal_title>Br J Cancer</journal_title>
          <author>Silva-Santos</author>
          <volume>109</volume>
          <issue>10</issue>
          <cYear>2013</cYear>
          <article_title>MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis</article_title>
        </citation>
        <citation key="ref25">
          <journal_title>Eur Urol</journal_title>
          <author>Youssef</author>
          <volume>59</volume>
          <issue>5</issue>
          <cYear>2011</cYear>
          <article_title>Accurate molecular classification of kidney cancer subtypes using microRNA signature</article_title>
        </citation>
        <citation key="ref26">
          <journal_title>Diagn Mol Pathol</journal_title>
          <author>Powers</author>
          <volume>20</volume>
          <issue>2</issue>
          <cYear>2011</cYear>
          <article_title>Molecular classification of adult renal epithelial neoplasms using microRNA expression and virtual karyotyping</article_title>
        </citation>
        <citation key="ref27">
          <journal_title>Urol Oncol</journal_title>
          <author>Ma</author>
          <volume>33</volume>
          <issue>4</issue>
          <cYear>2015</cYear>
          <article_title>MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma</article_title>
        </citation>
        <citation key="ref28">
          <journal_title>Tumour Biol</journal_title>
          <author>Yuan</author>
          <volume>35</volume>
          <issue>12</issue>
          <cYear>2014</cYear>
          <article_title>Elevated microRNA-185 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in clear cell renal cell carcinoma</article_title>
        </citation>
        <citation key="ref29">
          <journal_title>Proc Natl Acad Sci U S A</journal_title>
          <author>Harris</author>
          <volume>105</volume>
          <issue>5</issue>
          <cYear>2008</cYear>
          <article_title>MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1</article_title>
        </citation>
        <citation key="ref30">
          <journal_title>Dev Cell</journal_title>
          <author>Fish</author>
          <volume>15</volume>
          <issue>2</issue>
          <cYear>2008</cYear>
          <article_title>miR-126 regulates angiogenic signaling and vascular integrity</article_title>
        </citation>
        <citation key="ref31">
          <journal_title>Am J Pathol</journal_title>
          <author>Khella</author>
          <volume>185</volume>
          <issue>3</issue>
          <cYear>2015</cYear>
          <article_title>Low expression of miR-126 is a prognostic marker for metastatic clear cell renal cell carcinoma</article_title>
        </citation>
        <citation key="ref32">
          <journal_title>Blood</journal_title>
          <author>Chen</author>
          <volume>111</volume>
          <issue>3</issue>
          <cYear>2008</cYear>
          <article_title>Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5</article_title>
        </citation>
        <citation key="ref33">
          <journal_title>Ann Oncol</journal_title>
          <author>Bex</author>
          <volume>28</volume>
          <issue>4</issue>
          <cYear>2017</cYear>
          <article_title>Adjuvant sunitinib in renal cell carcinoma: from evidence to recommendation</article_title>
        </citation>
      </citation_list>
    </posted_content>
  </body>
</doi_batch>
